Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV001011815 | SCV001172182 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-05-01 | criteria provided, single submitter | clinical testing | The p.K494N variant (also known as c.1482G>T), located in coding exon 13 of the CHEK2 gene, results from a G to T substitution at nucleotide position 1482. The lysine at codon 494 is replaced by asparagine, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
| Invitae | RCV001059466 | SCV001224090 | uncertain significance | Familial cancer of breast | 2023-08-22 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 819340). This variant has not been reported in the literature in individuals affected with CHEK2-related conditions. This variant is present in population databases (rs767043399, gnomAD 0.002%). This sequence change replaces lysine, which is basic and polar, with asparagine, which is neutral and polar, at codon 494 of the CHEK2 protein (p.Lys494Asn). |